Journal Mobile Options
Table of Contents
Vol. 27, Suppl. 1, 2009
Issue release date: March 2010
Dig Dis 2009;27(suppl 1):99–103
(DOI:10.1159/000268128)

Bacterial Flora in Inflammatory Bowel Disease

Marteau P.
University Paris 7 and AP-HP, Medicosurgical Department of Digestive Diseases, Lariboisière Hospital, Paris, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The pathogenesis of inflammatory bowel disease (IBD) involves an interaction between host susceptibility (which is partly genetically determined), mucosal immunity and the intestinal milieu. Micro-organisms have physiological effects on mucosal structure, epithelial turnover, the intestinal immune cells and, thus, on many intestinal functions. Toll-like receptors and nucleotide oligomerisation-binding domain proteins in host cells recognise specific bacterial molecules and modify the immune response. Human studies have repeatedly shown that the microbiota of patients with IBD differs from that of controls and is unstable, both in the intestinal lumen and at the surface of the mucosa. A single pathogen has not been identified, but potentially pro-inflammatory micro-organisms have been found in samples from IBD patients more often than from healthy controls. These include Mycobacterium paratuberculosis, and enteroadherent and invasive Escherichia coli in Crohn’s disease (CD). Ecological descriptions of the microbiota present in patients with IBD (either in the faeces or adherent to the mucosa) have repeatedly reported a decrease in usually dominant bacteria, especially those from the dominant phylum Firmicutes. A decrease in the biodiversity of Firmicutes has been observed in CD, while a recent study has shown that a decrease in Firmicutes, especially Faecalibacterium prausnitzii, was associated with CD and the post-operative recurrence of CD lesions in the ileum. Taken together, these results suggest that dysbiosis, or an imbalance within the (dominant) intestinal microbiota, may favour IBD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Crohn BB, Ginzburg L, Oppenheimer GD: Regional ileitis: a pathologic and clinical entity. JAMA 1932;99:1323–1329.

    External Resources

  2. Packey CD, Sartor RB: Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J Intern Med 2008;263:597–606.
  3. Noomen CG, Hommes DW, Fidder HH: Update on genetics in inflammatory disease. Best Pract Res Clin Gastroenterol 2009;23:233–243.
  4. Naser SA, Ghobrial G, Romero C, Valentine JF: Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn’s disease. Lancet 2004;364:1039–1044.
  5. Bentley RW, Keenan JI, Gearry RB, Kennedy MA, Barclay ML, Roberts RL: Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn’s disease and control subjects. Am J Gastroenterol 2008;103:1168– 1172.
  6. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 2004;127:412–421.
  7. Martinez-Medina M, Aldeguer X, Lopez-Siles M, González-Huix F, López-Oliu C, Dahbi G, Blanco JE, Blanco J, Garcia-Gil LJ, Darfeuille-Michaud A: Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn’s disease. Inflamm Bowel Dis 2009;15:872–882.
  8. Laharie D, Asencio C, Asselineau J, Bulois P, Bourreille A, Moreau J, Bonjean P, Lamarque D, Pariente A, Soulé JC, Charachon A, Coffin B, Perez P, Mégraud F, Zerbib F: Association between entero-hepatic Helicobacter species and Crohn’s disease: a prospective cross-sectional study. Aliment Pharmacol Ther 2009;30:283–293.
  9. Issa M, Ananthakrishnan AN, Binion DG: Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1432–1442.
  10. Hugot JP, Alberti C, Berrebi D, Bingen E, Cézard JP: Crohn’s disease: the cold chain hypothesis. Lancet 2003;362:2012–2015.
  11. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N: Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003;52:79–83.
  12. Minami M, Ando T, Okamoto A, Sasaki N, Ohkura T, Torii K, Hasegawa T, Ohta M, Goto H: Seroprevalence of Fusobacterium varium in ulcerative colitis patients in Japan. FEMS Immunol Med Microbiol 2009;56: 67–72.
  13. Llopis M, Antolin M, Guarner F, Salas A, Malagelada JR: Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut 2005;54:955–959.
  14. Heuvelin E, Lebreton C, Grangette C, Pot B, Cerf-Bensussan N, Heyman M: Mechanisms involved in alleviation of intestinal inflammation by bifidobacterium breve soluble factors. PLoS One 2009;4:e5184.
  15. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731–16736.
  16. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J: Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009;15:1183–1189.
  17. Mangin I, Bonnet R, Seksik P, Rigottier-Gois L, Sutren M, Bouhnik Y, Neut C, Collins MD, Colombel JF, Marteau P, Doré J: Molecular inventory of faecal microflora in patients with Crohn’s disease. FEMS Microbiol Ecol 2004;50:25–36.
  18. Marteau P, Pochart P, Doré J, Béra-Maillet C, Bernalier A, Corthier G: Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl Environ Microbiol 2001;67:4939–4942.
  19. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005;43:3380–3389.
  20. Zoetendal EG, Akkermans AD, De Vos WM: Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998;64:3854–3859.
  21. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al: Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut 2003;52:237–242.
  22. Maukonen J, Satokari R, Mättö J, Söderlund H, Mattila-Sandholm T, Saarela M: Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006;55:625–633.
  23. Scanlan PD, Shanahan F, O’Mahony C, Marchesi JR: Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn’s disease. J Clin Microbiol 2006;44:3980–3988, erratum in J Clin Microbiol 2007;45:1671.
  24. De La Cochetière MF, Durand T, Lepage P, Bourreille A, Galmiche JP, Doré J: Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol 2005;43:5588–5592.
  25. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, Ugarte E, Muñoz-Tamayo R, Paslier DL, Nalin R, Dore J, Leclerc M: Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009;11:2574–2584.
  26. Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N, Guarner F, Malagelada JR: Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol 2008;103:643–648.
  27. Tamboli CP, Neut C, Desreumaux P, Colombel JF: Dysbiosis as a prerequisite for IBD. Gut 2004;53:1057.
  28. Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y: Active Crohn’s disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008;14:147–161.
  29. Lay C, Rigottier-Gois L, Holmstrøm K, Rajilic M, Vaughan EE, de Vos WM, Collins MD, Thiel R, Namsolleck P, Blaut M, Doré J: Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol 2005;71:4153–4155.
  30. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW: Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum. ISME J 2007;1:403–418.
  31. Sasaki M, Sitaraman SV, Babbin BA, Gerner-Smidt P, Ribot EM, Garrett N, Alpern JA, Akyildiz A, Theiss AL, Nusrat A, Klapproth JM: Invasive Escherichia coli are a feature of Crohn’s disease. Lab Invest 2007;87:1042–1054.
  32. Rhodes JM: The role of Escherichia coli in inflammatory bowel disease. Gut 2007;56:610–612.
  33. Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Dore J: Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:106–111.
  34. Kotlowski R, Bernstein CN, Sepehri S, Krause DO: High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007;56:669–675.
  35. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J: Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006;55:205–211.
  36. Mangin I, Bonnet R, Seksik P, Rigottier-Gois L, Sutren M, Bouhnik Y, Neut C, Collins MD, Colombel JF, Marteau P, Doré J: Molecular inventory of faecal microflora in patients with Crohn’s disease. FEMS Microbiol Ecol 2004;50:25–36.
  37. Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Dore J: Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:106–111.
  38. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM: Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002;68:3401–3407.
  39. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44–54.
  40. Lepage P, Seksik P, Sutren M, de la Cochetiere MF, Jian R, Marteau P, et al: Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm Bowel Dis 2005;11:473–480.
  41. Vasquez N, Mangin I, Lepage P, Seksik P, Duong JP, Blum S, Schiffrin E, Suau A, Allez M, Vernier G, Tréton X, Doré J, Marteau P, Pochart P: Patchy distribution of mucosal lesions in ileal Crohn’s disease is not linked to differences in the dominant mucosa-associated bacteria: a study using fluorescence in situ hybridization and temporal temperature gradient gel electrophoresis. Inflamm Bowel Dis 2007;13:684–692.
  42. Seksik P, Lepage P, de la Cochetiere MF, Bourreille A, Sutren M, Galmiche JP, et al: Search for localized dysbiosis in Crohn’s disease ulcerations by temporal temperature gradient gel electrophoresis of 16S rRNA. J Clin Microbiol 2005;43:4654–4658.
  43. Sokol H, Vasquez N, Hoyeau N, Seksik P, Beaugerie L, Lavergne-Slove A, Pochart P, Marteau P: Crypt abscess associated microbiota in inflammatory bowel disease and acute self-limited colitis. World J Gastroenterol, in press.
  44. Carvalho FA, Barnich N, Sivignon A, Darcha C, Chan CH, Stanners CP, Darfeuille-Michaud A: Crohn’s disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 2009;206:2179–2189.
  45. Malchow HA: Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 1997;25:653–658.
  46. Travis SPL, Stange EF, Lemann M, et al: European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24–62.
  47. Sans M: Probiotics for inflammatory bowel disease: a critical appraisal. Dig Dis 2009; 27(suppl 1):111–114.

    External Resources

  48. Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al: Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856–861.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50